• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » A New COG Model In Brazil

A New COG Model In Brazil

March 23, 2007
CenterWatch Staff

A new oncology-focused contract research organization (CRO) may have found an ideal way to tap into the large patient population participating in Brazil’s public healthcare system.

Oncopartners, a management-funded U.S. company with a wholly owned Brazilian subsidiary, has entered an exclusive worldwide partnership with Instituto Brasileiro de Pesquisa em Câncer (IBPC), a non-profit entity created to build a network of oncology clinical researchers from 18 public cancer hospitals in Brazil.

Oncopartners has funded and designed the IBPC infrastructure to support international clinical research in each of the public hospitals. Those sites treat more than 30,000 new incidences of cancer annually.

This is a brand-new CRO model for Latin America and an important one. Pharmaceutical and biotechnology companies usually have the option of outsourcing an entire clinical trial, and often do, so the model for a particular country, especially in an emerging region, can be all-important.

According to Michael Choukas, president and CEO, Oncopartners, 70% of Brazil’s 180 million-plus population has access to healthcare through the public system, and the country’s national formulary has not added a significant new oncology treatment since 2000.

This environment offers centralized access to a motivated patient and physician population, offering one budget and contract — a real opportunity for Oncopartners.

Normally, big pharma and biotechs would have to create a budget and contract for each hospital, a labor-intensive process at a time when faster time to market for drugs is an important metric that emerging countries offer.

As I’ve written in an earlier post, cooperative oncology groups (COGs) in the U.S. are receiving less funding from the National Cancer Institute and have had to make tough cuts to their programs, which will cause more pressure on privately owned sites to enroll cancer patients. These COGs enroll half the patients for oncology trials in the U.S.

Cutbacks have led the COGs to announce that they will have to shut down 95 — or nearly half — of the oncology clinical trials they conduct annually. This would eliminate up to 3,000 —out of 20,000 — patient slots in clinical trials across all cancers, but mainly those for rarer cancers such as sarcoma, some childhood tumors, and head and neck cancers.

Emerging markets in clinical research, such as Brazil, will start to pick up the slack when COG-like businesses, such as Oncopartners, flourish there. Choukas sees his CRO scaling to several thousand patients a year fairly quickly and sees no reason why Brazil couldn’t contribute 20% to 25% of the patients in a large phase III trial.

“Historically, that’s been unusual because much of the research has happened in the private hospitals, which don’t have that kind of patient flow. The research that’s gone on in the public hospitals—and there’s been a lot of it—has not had the benefit of centralized support and resources and has not achieved the kind of enrollment metrics we’re planning on,” he said.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing